☆ 4.7 Review

Unveiling Novel Avenues in mTOR-Targeted Therapeutics: Advancements in Glioblastoma Treatment

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Related references

Note: Only part of the references are listed.
Review Biotechnology & Applied Microbiology

Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects

Estela Pineda et al.

Summary: Treating glioblastomas is challenging and there are currently no effective alternative treatments. The main difficulties in treatment arise from the low incidence of the disease, age and neurological symptoms of patients, and issues related to the drugs themselves.

ONCOTARGETS AND THERAPY (2023)

Add to Collection
Article Biochemistry & Molecular Biology

Exosomes derived from rapamycin-treated 4T1 breast cancer cells induced polarization of macrophages to M1 phenotype

Majdedin Ghalavand et al.

Summary: This study investigated the role of the tumor microenvironment and purified exosomes in M2 to M1 macrophage polarization, highlighting its potential as cancer immunotherapy. The results demonstrated that treatment with rapamycin-exosomes induced polarization of M2 macrophages to M1, leading to improved macrophage functionality.

BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY (2023)

Add to Collection
Article Cell & Tissue Engineering

Engineered exosome-mediated messenger RNA and single-chain variable fragment delivery for human chimeric antigen receptor T-cell engineering

Ke Si et al.

Summary: The authors developed an exosome delivery platform using the bacteriophage MS2 system and the highly expressed lysosome-associated membrane protein 2 isoform B on exosomes. This platform successfully achieved specific loading and delivery of mRNA into target cells, as well as the expression of specific proteins, and activated primary T cells in a similar way to commercial magnetic beads. It provides a novel strategy for the production of CAR T cells in vivo.

CYTOTHERAPY (2023)

Add to Collection
Review Medicine, General & Internal

Glioblastoma and Other Primary Brain Malignancies in Adults: A Review

Lauren R. Schaff et al.

Summary: Malignant primary brain tumors cause a significant number of deaths in the United States each year, with glioblastomas being the most common type. The symptoms of these tumors can include headaches, seizures, neurocognitive impairment, and focal neurologic deficits. Diagnosis and treatment depends on the tumor type, with surgery, chemotherapy, and radiation often being used.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection
Review Neurosciences

Exosomes: Promising Delivery Tools for Overcoming Blood-Brain Barrier and Glioblastoma Therapy

Seyyed Hossein Khatami et al.

Summary: Gliomas account for 80% of all lethal primary brain tumors and are categorized based on their cell of origin. Glioblastoma, an astrocytic tumor, has a poor prognosis due to the presence of the blood-brain barrier and blood-brain tumor barrier. Novel drug delivery strategies, including the use of exosomes, have been developed to overcome these barriers and target cancer cells after resection in glioblastoma therapy.

MOLECULAR NEUROBIOLOGY (2023)

Add to Collection
Article Cell Biology

Dual Targeting of EGFR and MTOR Pathways Inhibits Glioblastoma Growth by Modulating the Tumor Microenvironment

Maxim Sidorov et al.

Summary: This study identified a combination therapy of erlotinib and MLN0128 as an effective treatment for EGFR-driven glioblastomas. The combination therapy inhibited tumor cell growth and modulated the immune tumor microenvironment. The findings suggest that co-targeting EGFR and MTOR using clinically available drugs is a promising treatment approach for glioblastomas.

CELLS (2023)

Add to Collection
Review Medicine, General & Internal

Personalised therapeutic approaches to glioblastoma: A systematic review

Oliver D. Mowforth et al.

Summary: Personalised glioblastoma therapies have not shown consistent evidence of survival benefit, and there is a high risk of bias in the available evidence.

FRONTIERS IN MEDICINE (2023)

Add to Collection
Review Biochemistry & Molecular Biology

Personalized Treatment of Glioblastoma: Current State and Future Perspective

Alen Roncevic et al.

Summary: Glioblastoma (GBM) is a highly aggressive glial tumor in the central nervous system. Current standard treatments only offer a median survival of 15 months. Tissue samples obtained during surgery are crucial for GBM diagnosis, and there is significant room for improvement in the current treatment methods.

BIOMEDICINES (2023)

Add to Collection
Review Biochemistry & Molecular Biology

Expression of mTOR in normal and pathological conditions

A. Marques-Ramos et al.

Summary: mTOR, a protein discovered in 1991, plays a key role in maintaining cellular homeostasis by integrating intra- and extracellular signals. Dysregulation of mTOR pathway is implicated in various human diseases. Research on mTOR gene expression regulation and its potential as a biomarker for diagnosis, prognosis and therapeutics response is emerging.

MOLECULAR CANCER (2023)

Add to Collection
Article Chemistry, Physical

Glioblastoma cell-derived exosomes functionalized with peptides as efficient nanocarriers for synergistic chemotherapy of glioblastoma with improved biosafety

Ying Zhou et al.

Summary: This article introduces a new drug delivery system, Exo@TDPs, which is developed by engineering glioblastoma cell-derived exosomes with improved biosafety. It demonstrates that Exo@TDPs can successfully penetrate the blood-brain barrier, target glioblastoma cells, and effectively release therapeutic drugs, resulting in the suppression of tumor growth and prolonged survival time in mouse models.

NANO RESEARCH (2023)

Add to Collection
Article Instruments & Instrumentation

Sirolimus-loaded exosomes as a promising vascular delivery system for the prevention of post-angioplasty restenosis

Fatemeh Mehryab et al.

Summary: Restenosis remains the main cause of failure in arterial disease treatment. Sirolimus-loaded exosomes were developed as a hopeful strategy to prevent restenosis. These exosomes were loaded with Sirolimus and characterized for their physicochemical, pharmaceutical, and biological properties. In vitro and in vivo studies showed the efficacy of Sirolimus-loaded exosomes in reducing restenosis.

DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2023)

Add to Collection
Review Biochemistry & Molecular Biology

Small Molecule Targeting Immune Cells: A Novel Approach for Cancer Treatment

Shilpi Singh et al.

Summary: This article introduces strategies to modify immune cells within the tumor microenvironment using small molecules, potentially revolutionizing therapeutic interventions and enhancing the anti-tumor response.

BIOMEDICINES (2023)

Add to Collection
Review Oncology

Challenges in glioblastoma research: focus on the tumor microenvironment

Andreas Bikfalvi et al.

Summary: Glioblastoma (GBM) is a highly lethal brain tumor, and recent studies have emphasized the importance of the tumor microenvironment (TME) as a therapeutic target. However, a comprehensive understanding of the different cellular and molecular components involved in the GBM TME and their interactions is still needed for the development of more effective treatments. This review presents a comprehensive report on the GBM TME, combining the contributions of researchers and physicians in France, and provides a holistic view of the subject by describing the specific features of the GBM TME at the cellular, molecular, and therapeutic levels.

TRENDS IN CANCER (2023)

Add to Collection
Review Medicine, Research & Experimental

Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy

Fatima Khan et al.

Summary: Glioblastoma (GBM) is the most aggressive tumor in the central nervous system and has a highly immunosuppressive tumor microenvironment (TME). Tumor-associated macrophages and microglia (TAMs) are dominant immune cells in the GBM TME and contribute to immunosuppression. Recent progress in single cell technologies allows for precise characterization of TAMs and identification of new TAM subpopulations with specific tumor-modulating functions in GBM. This review discusses TAM heterogeneity and plasticity in the TME and summarizes current potential therapeutic approaches targeting TAMs in GBM. The use of single cell technologies and functional studies is expected to accelerate the development of novel and effective TAM targeted therapeutics for GBM patients.

JOURNAL OF CLINICAL INVESTIGATION (2023)

Add to Collection
Article Engineering, Biomedical

Exosome-mediated delivery of transforming growth factor-β receptor 1 kinase inhibitors and toll-like receptor 7/8 agonists for combination therapy of tumors

Joo Hang Lee et al.

Summary: In this study, combination therapy using a TGF beta RI kinase inhibitor and TLR 7/8 agonist encapsulated within EXOs was shown to be effective in treating melanoma and prostate cancer. The therapy reduced tumor migration and triggered the release of proinflammatory cytokines, leading to reduced tumor growth and improved survival rate.

ACTA BIOMATERIALIA (2022)

Add to Collection
Article Biochemistry & Molecular Biology

Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma

Amir Barzegar Behrooz et al.

Summary: Glioblastoma (GBM) is a devastating type of brain tumor, and targeting the Wnt/β-catenin and PI3K/Akt/mTOR (PAM) signaling pathways, which play crucial roles in GBM progression and invasion, may provide important advancements in alternative treatment strategies for GBM.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection
Article Multidisciplinary Sciences

HIV-1 hypermethylated guanosine cap licenses specialized translation unaffected by mTOR

Gatikrushna Singh et al.

Summary: This study reveals the relationship between incomplete processing and hypermethylation of HIV-1 transcripts, as well as the role of trimethylguanosine synthetase-1 in HIV-1 infectivity and protein synthesis. The study also uncovers the interaction between nuclear RNA helicase A and the shape of the 5' untranslated region primer binding site, and the relationship between HIV-1 virion protein synthesis and host translation.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Add to Collection
Article Materials Science, Biomaterials

Delivery of siRNA based on engineered exosomes for glioblastoma therapy by targeting STAT3

Shi-Fu Liang et al.

Summary: This paper presents the potential use of Angiopep-2 (An2)-functionalized siRNA-loaded exosomes as a therapeutic agent for glioblastoma treatment. The experimental results demonstrate the superior properties of Exo-An2-siRNA, including high blood stability, efficient cellular uptake, and outstanding blood-brain barrier penetration ability.

BIOMATERIALS SCIENCE (2022)

Add to Collection
Article Pharmacology & Pharmacy

AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug Sitagliptin for the Management of Hepatocellular Carcinoma

Eslam E. Abd El-Fattah et al.

Summary: This study demonstrates that sitagliptin inhibits the activation of HIF-1α by interfering with the AKT-AMPKα-mTOR axis and interrupting IKKβ, P38α, and ERK1/2 signals. Sitagliptin prolongs survival, improves liver function, inhibits angiogenesis and tissue invasion, promotes apoptosis, inhibits proliferation, reduces inflammation, and has antifibrotic potential.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection
Article Instruments & Instrumentation

Development of a novel rapamycin loaded nano- into micro-formulation for treatment of lung inflammation

Emanuela Fabiola Craparo et al.

Summary: This paper details the design and production of a novel formulation of the drug rapamycin based on nano into micro (NiM) particles. The formulation shows promise in the treatment of lung diseases and has good potential for local administration to the lungs.

DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2022)

Add to Collection
Review Immunology

mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment

Sahar Mafi et al.

Summary: mTOR serves as a downstream mediator in the PI3K/Akt signaling pathways and plays a vital role in regulating cellular functions. Dysregulation of mTOR pathway is frequently observed in human tumors and targeting this pathway has been considered as a potential therapeutic option. It has been discovered that mTOR has a crucial regulatory role in immune responses, affecting the phenotypic and functional reprogramming of tumor-associated immune cells in the tumor microenvironment.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection
Review Pharmacology & Pharmacy

Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds

Hui Liu et al.

Summary: This article introduces the advantages of small molecule inhibitors in the treatment of glioblastoma and discusses the related targets of major pathways. It also discusses the recent advances in temozolomide resistance and drug combination, and reviews the research progress of other therapeutic methods to provide a more comprehensive understanding of the treatment landscape of glioblastoma.

ACTA PHARMACEUTICA SINICA B (2022)

Add to Collection
Article Engineering, Biomedical

A CAR T-inspiring platform based on antibody-engineered exosomes from antigen-feeding dendritic cells for precise solid tumor therapy

Miao Fan et al.

BIOMATERIALS (2022)

Add to Collection
Article Medicine, Research & Experimental

Development of rapamycin-encapsulated exosome-mimetic nanoparticles-in-PLGA microspheres for treatment of hemangiomas

Haitao Li et al.

Summary: The study developed rapamycin-encapsulated macrophage-derived exosomes mimic nanoparticles to achieve continuous targeted therapy of hemangiomas. The nanoparticles showed effective inhibition of cellular proliferation, induced cellular apoptosis, and suppressed expression of angiogenesis factors in hemangioma stem cells.

BIOMEDICINE & PHARMACOTHERAPY (2022)

Add to Collection
Review Oncology

Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review)

Marsel Khabibov et al.

Summary: This review aims to summarize the major signaling pathways and genetic abnormalities involved in the pathogenesis of glioblastoma and the therapies that target these pathways. Despite limited treatment options, significant advancements in understanding GBM biology in the past two decades provide hope for improved therapies.

INTERNATIONAL JOURNAL OF ONCOLOGY (2022)

Add to Collection
Review Oncology

Emerging therapies for glioblastoma: current state and future directions

Liang Rong et al.

Summary: Glioblastoma (GBM) is a common brain tumor with poor prognosis. Immunotherapy, including immune checkpoint blockade, CAR T cell therapy, oncolytic virotherapy, and vaccine therapy, has shown promising results in improving GBM outcomes. Techniques to overcome the blood-brain barrier for targeted delivery are also being tested. This article reviews the rationales for these therapies, potential novel agents, current status of trials, and discusses challenges and future perspectives in glioblastoma immuno-oncology.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Add to Collection
Article Chemistry, Multidisciplinary

Apoptotic Body-Mediated Intracellular Delivery Strategy for Enhanced STING Activation and Improved Tumor Immunogenicity

Peng Bao et al.

Summary: This study presents a nanovaccine platform that tackles the challenges of conventional STING agonists, leading to enhanced tumor-specific antigen presentation ability and improved immune response.

NANO LETTERS (2022)

Add to Collection
Article Oncology

PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications

Esraa Mohamed et al.

Summary: The study highlights the value of proteomic assessment of signaling pathway activity in tumors as a means to identify relevant oncogenic pathways and potentially as a biomarker for identifying aggressive disease.

NEURO-ONCOLOGY (2022)

Add to Collection
Article Oncology

Evaluating adipose-derived stem cell exosomes as miRNA drug delivery systems for the treatment of bladder cancer

Tianyao Liu et al.

Summary: This study suggests that adipose-derived stem cell exosomes could be a promising therapeutic strategy for bladder cancer treatment, delivering miR-138-5p to suppress tumor growth.

CANCER MEDICINE (2022)

Add to Collection
Article Chemistry, Multidisciplinary

Synchronous Disintegration of Ferroptosis Defense Axis via Engineered Exosome-Conjugated Magnetic Nanoparticles for Glioblastoma Therapy

Boyan Li et al.

Summary: A novel composite therapeutic platform combining magnetic nanoparticles and engineered exosomes is proposed for GBM treatment, aiming to improve the penetration through the blood-brain barrier and enhance tumor targeting ability for effective ferroptosis therapy.

ADVANCED SCIENCE (2022)

Add to Collection
Article Immunology

Therapeutic Effect of Rapamycin-Loaded Small Extracellular Vesicles Derived from Mesenchymal Stem Cells on Experimental Autoimmune Uveitis

Huan Li et al.

Summary: Rapa-sEVs, delivered through subconjunctival injection, show promising therapeutic effects on autoimmune uveitis by reducing ocular inflammatory cell infiltration.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection
Review Oncology

Epidemiology of Glioblastoma Multiforme-Literature Review

Szymon Grochans et al.

Summary: Glioblastoma multiforme (GBM) is a highly aggressive malignancy with a median overall survival of approximately 15 months. This review analyzes the pathogenesis and epidemiological data of GBM, including age, gender, and tumor location. The data suggest that GBM is a higher-grade primary brain tumor and is significantly more common in men. Despite advancements in medicine, the risk of being diagnosed with glioma increases with age and median survival remains low. Additionally, the influence of stimulants, certain medications (such as NSAIDs), cell phone use, and exposure to heavy metals on GBM is difficult to determine clearly.

CANCERS (2022)

Add to Collection
Review Pharmacology & Pharmacy

Targeting Protein Kinases and Epigenetic Control as Combinatorial Therapy Options for Advanced Prostate Cancer Treatment

Soghra Bagheri et al.

Summary: Prostate cancer, when it spreads to the bone, is known as metastatic bone cancer. Currently, effective treatment options are still lacking for advanced/metastatic PC. However, understanding the molecular events that contribute to PC progression provides hope for the development of new treatment strategies. Protein kinases play crucial roles in the growth, proliferation, and metastases of prostatic tumors, making combinatorial therapy with PK inhibitors a potential treatment approach. Additionally, epigenetic pathways are also involved in PC, suggesting another potential combination treatment strategy.

PHARMACEUTICS (2022)

Add to Collection
Article Cell Biology

Tumour-derived extracellular vesicle membrane hybrid lipid nanovesicles enhance siRNA delivery by tumour-homing and intracellular freeway transportation

Xin Zhou et al.

Summary: This study successfully isolated TDEV membranes from hepatocellular carcinoma cells and fabricated innovative TDEV membrane hybrid lipid nanovesicles (LEVs) for precise delivery to tumors and efficient siRNA transfection. The LEVs, equipped with 'homing' targeting ability, showed improved siRNA delivery efficiency compared to liposomes. In animal experiments, siRNA loaded LEVs demonstrated enhanced antitumor efficacy in hepatocellular carcinoma tumors.

JOURNAL OF EXTRACELLULAR VESICLES (2022)

Add to Collection
Review Biochemistry & Molecular Biology

The Hallmarks of Glioblastoma: Heterogeneity, Intercellular Crosstalk and Molecular Signature of Invasiveness and Progression

Filippo Torrisi et al.

Summary: This article discusses the latest version of the World Health Organization's classification of central nervous system tumors in 2021, focusing on the biological and molecular mechanisms and tumor hallmarks of glioblastoma. The research findings indicate that the identification of glioblastoma subtypes has not led to personalized therapies and there have been no improvements in overall survival, highlighting unresolved issues. However, the evidence presented offers a promising perspective for understanding tumor pathophysiology and driving the development of new therapeutic strategies and approaches.

BIOMEDICINES (2022)

Add to Collection
Article Oncology

Extracellular vesicles as source for the identification of minimally invasive molecular signatures in glioblastoma

Elisabeth Rackles et al.

Summary: The analysis of extracellular vesicles (EVs) as a source of cancer biomarkers is a promising field, providing low-invasive biomarkers. EVs, present in most body fluids and released by all cell types, including cancer cells, can serve as a potential source of reliable biomarkers for cancer. EV biomarkers in liquid biopsy can complement current medical technologies for cancer diagnosis, prognosis, and therapy monitoring, particularly for glioblastoma.

SEMINARS IN CANCER BIOLOGY (2022)

Add to Collection
Article Biophysics

Tumor-derived exosomes reversing TMZ resistance by synergistic drug delivery for glioma-targeting treatment

Ruoning Wang et al.

Summary: This study proposes a new strategy for glioma treatment by using reassembly exosomes to carry drugs, which have good ability to cross the blood-brain barrier and tumor-targeting accumulation, overcoming drug resistance and triggering immune response.

COLLOIDS AND SURFACES B-BIOINTERFACES (2022)

Add to Collection
Article Pharmacology & Pharmacy

Lapatinib loaded exosomes as a drug delivery system in breast cancer

Nurdan Sena Degirmenci et al.

Summary: Exosomes, as natural vesicle nanocarriers, have the advantages of biocompatibility, natural form, high stability, and low toxicity. Loading chemotherapeutic drugs into exosomes derived from non-cancerous cells can enhance the effectiveness of drug treatment without interfering with the drug's mechanism of action.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY (2022)

Add to Collection
Review Oncology

Recent advances and limitations of mTOR inhibitors in the treatment of cancer

Eunus S. Ali et al.

Summary: The PI3K-Akt-mTOR signaling pathway plays a crucial role in various biological activities. Targeting mTOR with rapamycin-derived compounds has proven effective in suppressing mTOR activity and reducing cancer cell growth.

CANCER CELL INTERNATIONAL (2022)

Add to Collection
Review Cell Biology

mTORC1 beyond anabolic metabolism: Regulation of cell death

Jiajun Zhu et al.

Summary: In this review, Zhu et al. provide an overview of the current understanding of how mTORC1 activity is connected to cell death regulation through metabolic and signaling pathways. The authors focus on the interaction between mTORC1 and ferroptosis, an iron-dependent cell death program, and highlight the importance of further investigating the interplay between mTORC1 and cell death pathways.

JOURNAL OF CELL BIOLOGY (2022)

Add to Collection
Article Cell Biology

Inhibition of mTOR signaling protects human glioma cells from hypoxia-induced cell death in an autophagy-independent manner

Iris Dive et al.

Summary: Under conditions of hypoxia and starvation, autophagy is strongly induced and further enhanced by mTOR inhibition in glioma cells. While the mTOR inhibitor torin2 enhances glioma cell survival, co-treatment with torin2 and the autophagy inhibitor bafilomycin A1 fails to promote cell death. Treatment with bafilomycin A1 alone also protects glioma cells from cell death.

CELL DEATH DISCOVERY (2022)

Add to Collection
Review Biochemistry & Molecular Biology

Exosomes as Anticancer Drug Delivery Vehicles: Prospects and Challenges

Yubo Zhang et al.

Summary: Exosomes, a subset of extracellular vesicles, have emerged as potential drug delivery vehicles in cancer therapy due to their excellent properties. However, there are still challenges in their clinical application.

FRONTIERS IN BIOSCIENCE-LANDMARK (2022)

Add to Collection
Article Multidisciplinary Sciences

Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity

Sushrut Kamerkar et al.

Summary: Researchers have developed an engineered exosome therapeutic candidate that selectively silences the expression of STAT6 gene in tumor-associated macrophages (TAMs). This drug shows high efficacy in inhibiting tumor growth and inducing complete remissions in colorectal cancer and hepatocellular carcinoma models. It also remodels the tumor microenvironment and triggers a specific immune response mediated by CD8 T cells.

SCIENCE ADVANCES (2022)

Add to Collection
Review Oncology

A review of glioblastoma immunotherapy

Ravi Medikonda et al.

Summary: Current immunotherapy treatments for glioblastoma, including checkpoint inhibitors and vaccine therapy, have shown disappointing results in clinical trials due to the highly immunosuppressive environment and therapy resistance mechanisms of the tumor. Ongoing research is focusing on exploring combination therapies and novel treatment strategies beyond immune checkpoint therapies, as well as establishing synergy between immunotherapy and current standard of care to improve treatment outcomes. Recent advances in personalized neoantigen vaccines suggest a shift towards personalized, patient-specific treatment for glioblastoma.

JOURNAL OF NEURO-ONCOLOGY (2021)

Add to Collection
Article Chemistry, Medicinal

Combined Treatment with Acalabrutinib and Rapamycin Inhibits Glioma Stem Cells and Promotes Vascular Normalization by Downregulating BTK/mTOR/VEGF Signaling

Yu-Kai Su et al.

Summary: The study evaluated the effects of BTK and mTOR inhibition on glioblastoma (GBM) and found a synergistic relationship between acalabrutinib and rapamycin, which effectively suppressed CSC phenotypes and angiogenesis potential, promoting vascular normalization for chemoresistant/radioresistant GBM.

PHARMACEUTICALS (2021)

Add to Collection
Article Chemistry, Multidisciplinary

Self-Activatable Photo-Extracellular Vesicle for Synergistic Trimodal Anticancer Therapy

Jingjing Ding et al.

Summary: An engineered self-activatable photo-EV for synergistic trimodal anticancer therapy has been reported, which utilizes M1 EVs to simultaneously load multiple drugs, achieving synergism of immunotherapy, photodynamic therapy, and chemotherapy with great promise in fighting cancers.

ADVANCED MATERIALS (2021)

Add to Collection
Article Biochemistry & Molecular Biology

Pharmacological Inhibition of mTORC2 Reduces Migration and Metastasis in Melanoma

Jessica Guenzle et al.

Summary: This study demonstrates the significant reduction in migration, invasion, and proliferation of melanoma cells upon specific inhibition of mTORC2 using the novel inhibitor JR-AB2-011, leading to cell death through non-apoptotic pathways. In a syngeneic murine metastasis model, therapy with JR-AB2-011 showed a remarkable decrease in liver metastasis, highlighting the potential of pharmacological blockade of mTORC2 as a novel anti-cancer approach for melanoma liver metastasis.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection
Review Biochemistry & Molecular Biology

The Role of mTOR Signaling as a Therapeutic Target in Cancer

Nadezhda V. Popova et al.

Summary: This review summarizes the current information on the role of phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling in cancer as a potential target for new therapy options. The mTOR and PI3K/AKT/mTORC1 (mTOR complex 1) signaling pathways are critical for regulating fundamental cell processes, and their deregulation is implicated in cancer, metabolic dysregulation, and aging. The review also discusses recent data on the structure and function of the mTOR pathway, mechanisms of deregulation in human cancers, and the use of PI3K/AKT/mTOR inhibitors in clinical studies for cancer treatment, including issues of resistance and adverse effects.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection
Review Oncology

A Review of Newly Diagnosed Glioblastoma

Bryan Oronsky et al.

Summary: Glioblastoma is an aggressive primary intra-axial brain tumor with poor prognosis, and current treatment involves surgery, radiotherapy, and chemotherapy. This review summarizes the characteristics, current treatment options, and potential future therapeutic prospects for the disease.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection
Article Cell Biology

Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery

Tin Chanh Pham et al.

Summary: The study presents a novel method for covalently conjugating EVs with targeting moieties using protein ligases, enabling specific delivery of therapeutic payloads to target cells without the need for genetic and chemical modifications. This approach shows promise for enhancing drug efficacy in cancer therapy by targeting specific receptors on cancer cells.

JOURNAL OF EXTRACELLULAR VESICLES (2021)

Add to Collection
Article Biotechnology & Applied Microbiology

Rapamycin-Loaded Lipid Nanocapsules Induce Selective Inhibition of the mTORC1-Signaling Pathway in Glioblastoma Cells

Delphine Sehedic et al.

Summary: The study investigates a novel method for the formulation of safe rapamycin nanocarriers and confirms its potential in cancer treatment. Results show that LNC-rapa selectively inhibits the mTORC1 signaling pathway in the U87MG glioblastoma model. Additionally, there are differences in the mTOR inhibition response to rapamycin under different oxygen concentration conditions.

FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2021)

Add to Collection
Review Pharmacology & Pharmacy

Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment

Lin Tang et al.

Summary: Glioblastoma (GBM) is a common malignant primary brain tumor with a poor prognosis. The current standard treatment regimen has limited efficacy, and new therapeutic approaches, such as nanotechnologies for overcoming the blood-brain barrier, hold promise for treating GBM.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection
Review Biochemistry & Molecular Biology

Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update

Mayra Colardo et al.

Summary: Gliomas are the most common and challenging malignant tumors of the central nervous system, with limited treatment efficacy and the development of resistance leading to tumor recurrence. Therefore, finding effective and well-tolerated pharmacological approaches is crucial in combating this disease.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection
Review Oncology

Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications

Benjamin T. Himes et al.

Summary: Glioblastoma (GBM) is the most common primary brain tumor in adults with a terrible prognosis. Immune suppression in many GBM patients has limited the effectiveness of immunotherapeutic agents, which have shown benefits in other cancers. Understanding tumor-mediated immune suppression is crucial for developing effective novel therapies for GBM, and overcoming this may be key for successful immunotherapy.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection
Article Biochemistry & Molecular Biology

The Bumpy Road towards mTOR Inhibition in Glioblastoma: Quo Vadis?

Kostas A. Papavassiliou et al.

Summary: GBM, a deadly brain tumor, has limited treatment options and mTOR pathway plays a crucial role in its pathogenesis. Initial attempts with first-generation mTOR inhibitors lacked significant success in clinical trials, but the development of next-generation inhibitors offers new hope for the potential of mTOR inhibitors in GBM.

BIOMEDICINES (2021)

Add to Collection
Article Multidisciplinary Sciences

Apoptotic body-mediated intercellular delivery for enhanced drug penetration and whole tumor destruction

Dongyang Zhao et al.

Summary: Chemotherapeutic nanomedicines can utilize apoptotic bodies to deliver remaining drugs to neighboring tumor cells, enhancing tumor penetration. By fabricating nanoparticles containing camptothecin and PR104A, the deep penetration of chemotherapeutic drugs can be improved to achieve complete tumor destruction.

SCIENCE ADVANCES (2021)

Add to Collection
Review Oncology

Combining mTOR Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment

Alexandre el Hage et al.

Summary: Studies have shown that mTOR inhibitors can promote or inhibit immune responses in certain contexts, helping to enhance the anticancer effects of immunotherapy. Various resistance mechanisms to mTOR inhibitors have been identified, highlighting the potential benefits of combination therapies.

CANCERS (2021)

Add to Collection
Article Cell Biology

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair

Shaolu Zhang et al.

Summary: This study demonstrated synergistic anticancer effects of PARP inhibitor and PI3K inhibitor on GBM cells, affecting HR molecule expression, repair efficiency, and apoptosis induction. The combination therapy showed significantly increased anti-tumor efficacy in cell and animal models, with complemented DNA damage response and drug accumulation. This combination therapy might represent a promising therapeutic approach for GBM.

CELL DEATH & DISEASE (2021)

Add to Collection
Article Biology

Regulation of human mTOR complexes by DEPTOR

Matthias Waelchli et al.

Summary: DEPTOR, a vertebrate-specific protein, acts as either an oncoprotein or tumor suppressor, playing crucial roles in metabolism, immunity, and cancer by interacting with mTOR through its structured regions. The interplay between DEPTOR and mTOR, involving multiple binding interfaces, provides insights into the diverse functions of DEPTOR in physiology and offers new avenues for targeting the mTOR-DEPTOR interaction in disease.

ELIFE (2021)

Add to Collection
Review Chemistry, Multidisciplinary

Exosomes as Naturally Occurring Vehicles for Delivery of Biopharmaceuticals: Insights from Drug Delivery to Clinical Perspectives

Arun Butreddy et al.

Summary: Exosomes, as nanosized vesicles, are emerging as drug delivery systems due to their natural origin and the ability to encapsulate biological molecules within the lipid bilayer membrane. However, challenges such as stability, production, drug loading, and clearance mechanisms may limit their clinical use.

NANOMATERIALS (2021)

Add to Collection
Review Pharmacology & Pharmacy

Targeting Glioblastoma: Advances in Drug Delivery and Novel Therapeutic Approaches

Eilam Yeini et al.

Summary: Glioblastoma (GB) is the most lethal type of primary tumor in the central nervous system, with highly invasive and angiogenic properties, leading to therapy resistance and disease relapse. The blood brain barrier restricts drug uptake, therefore, efforts are focusing on developing novel nanomedicines that can cross the BBB and target cancer cells.

ADVANCED THERAPEUTICS (2021)

Add to Collection
Article Pharmacology & Pharmacy

Engineered targeting tLyp-1 exosomes as gene therapy vectors for efficient delivery of siRNA into lung cancer cells

Jing Bai et al.

ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2020)

Add to Collection
Article Cardiac & Cardiovascular Systems

Rapamycin-Loaded Biomimetic Nanoparticles Reverse Vascular Inflammation

Christian Boada et al.

CIRCULATION RESEARCH (2020)

Add to Collection
Article Chemistry, Multidisciplinary

Systemic delivery of microRNA-21 antisense oligonucleotides to the brain using T7-peptide decorated exosomes

Gyeungyun Kim et al.

JOURNAL OF CONTROLLED RELEASE (2020)

Add to Collection
Article Chemistry, Multidisciplinary

Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis

Liuwan Zhao et al.

JOURNAL OF CONTROLLED RELEASE (2020)

Add to Collection
Article Oncology

MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway

Guohua Lou et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)

Add to Collection
Review Cell Biology

mTOR at the nexus of nutrition, growth, ageing and disease

Grace Y. Liu et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)

Add to Collection
Article Engineering, Biomedical

Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation

Zhaogang Yang et al.

NATURE BIOMEDICAL ENGINEERING (2020)

Add to Collection
Article Oncology

Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma

Kazuki Kuroshima et al.

CANCER SCIENCE (2020)

Add to Collection
Article Biotechnology & Applied Microbiology

Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer

Gaofeng Liang et al.

JOURNAL OF NANOBIOTECHNOLOGY (2020)

Add to Collection
Article Instruments & Instrumentation

A novel strategy for glioblastoma treatment combining alpha-cyano-4-hydroxycinnamic acid with cetuximab using nanotechnology-based delivery systems

Natalia N. Ferreira et al.

DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2020)

Add to Collection
Article Biochemistry & Molecular Biology

The mRNA encoding the JUND tumor suppressor detains nuclear RNA-binding proteins to assemble polysomes that are unaffected by mTOR

Gatikrushna Singh et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

Add to Collection
Review Biochemistry & Molecular Biology

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges

Zhilin Zou et al.

CELL AND BIOSCIENCE (2020)

Add to Collection
Article Chemistry, Medicinal

The effects of umbilical cord-derived macrophage exosomes loaded with cisplatin on the growth and drug resistance of ovarian cancer cells

Xiaohui Zhang et al.

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2020)

Add to Collection
Article Biochemistry & Molecular Biology

Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment

Anaelle A. Dumas et al.

EMBO JOURNAL (2020)

Add to Collection
Article Biochemistry & Molecular Biology

Extracellular vesicles engineered with valency-controlled DNA nanostructures deliver CRISPR/Cas9 system for gene therapy

Jialang Zhuang et al.

NUCLEIC ACIDS RESEARCH (2020)

Add to Collection
Review Genetics & Heredity

Regulation of mTORC2 Signaling

Wenxiang Fu et al.

GENES (2020)

Add to Collection
Review Oncology

Therapeutic Potential of Autophagy in Glioblastoma Treatment With Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway Inhibitors

Qin Xia et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection
Article Multidisciplinary Sciences

Combined PI3Kα-mTOR Targeting of Glioma Stem Cells

Frank D. Eckerdt et al.

SCIENTIFIC REPORTS (2020)

Add to Collection
Review Immunology

Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes

Yangzhi Qi et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection
Review Immunology

Reverse Signaling by MHC-I Molecules in Immune and Non-Immune Cell Types

Elke M. Muntjewerff et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection
Article Biochemical Research Methods

Exosome-mediated microRNA-497 delivery for anti-cancer therapy in a microfluidic 3D lung cancer model

Kyeongsoo Jeong et al.

LAB ON A CHIP (2020)

Add to Collection
Review Medicine, Research & Experimental

Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration

Jing Jin et al.

THERANOSTICS (2020)

Add to Collection
Editorial Material Cell Biology

mTOR Is Key to T Cell Transdifferentiation

Jiawei Yan et al.

CELL METABOLISM (2019)

Add to Collection
Article Multidisciplinary Sciences

Folliculin regulates mTORC1/2 and WNT pathways in early human pluripotency

J. Mathieu et al.

NATURE COMMUNICATIONS (2019)

Add to Collection
Review Oncology

Role of Notch Signaling Pathway in Glioblastoma Pathogenesis

Riccardo Bazzoni et al.

CANCERS (2019)

Add to Collection
Article Nanoscience & Nanotechnology

Ultrasound Facilitates Naturally Equipped Exosomes Derived from Macrophages and Blood Serum for Orthotopic Glioma Treatment

Lianmei Bai et al.

ACS APPLIED MATERIALS & INTERFACES (2019)

Add to Collection
Review Clinical Neurology

Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma

James Mooney et al.

WORLD NEUROSURGERY (2019)

Add to Collection
Review Oncology

Targeting mTOR for cancer therapy

Hui Hua et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)

Add to Collection
Article

EGFR and mTOR as therapeutic targets in glioblastoma

Michael W. Ronellenfitsch et al.

Oncotarget (2019)

Add to Collection
Review Clinical Neurology

Therapeutic Targeting of the Notch Pathway in Glioblastoma Multiforme

Zachary Gersey et al.

WORLD NEUROSURGERY (2019)

Add to Collection
Article Pharmacology & Pharmacy

Rapamycin-loaded polysorbate 80-coated PLGA nanoparticles: Optimization of formulation variables and in vitro anti-glioma assessment

Oscar Escalona-Rayo et al.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY (2019)

Add to Collection
Article Biotechnology & Applied Microbiology

Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy

Chunai Gong et al.

JOURNAL OF NANOBIOTECHNOLOGY (2019)

Add to Collection
Article Cell Biology

Rapamycin for longevity: opinion article

Mikhail V. Blagosklonny

AGING-US (2019)

Add to Collection
Article Biochemistry & Molecular Biology

mTORC2 links growth factor signaling with epigenetic regulation of iron metabolism in glioblastoma

Kenta Masui et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2019)

Add to Collection
Article Chemistry, Multidisciplinary

Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice

M. Garofalo et al.

JOURNAL OF CONTROLLED RELEASE (2019)

Add to Collection
Review Cell Biology

mTOR as a central hub of nutrient signalling and cell growth

Joungmok Kim et al.

NATURE CELL BIOLOGY (2019)

Add to Collection
Article Chemistry, Medicinal

Formulation and statistical optimization of intravenous temozolomide-loaded PEGylated liposomes to treat glioblastoma multiforme by three-level factorial design

Jigar Vanza et al.

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2018)

Add to Collection
Article Oncology

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

Andreas Wicki et al.

EUROPEAN JOURNAL OF CANCER (2018)

Add to Collection
Article Nanoscience & Nanotechnology

A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer

Yan Li et al.

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2018)

Add to Collection
Editorial Material Oncology

mTOR inhibition in glioblastoma: requiem for a dream?

Sam Babak et al.

NEURO-ONCOLOGY (2018)

Add to Collection
Review Pharmacology & Pharmacy

Current Challenges and Opportunities in Treating Glioblastoma

Andrea Shergalis et al.

PHARMACOLOGICAL REVIEWS (2018)

Add to Collection
Review Oncology

mTOR Cross-Talk in Cancer and Potential for Combination Therapy

Fabiana Conciatori et al.

CANCERS (2018)

Add to Collection
Article Clinical Neurology

Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance

Evan K. Noch et al.

WORLD NEUROSURGERY (2018)

Add to Collection
Review Biotechnology & Applied Microbiology

Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence

Carmen Mecca et al.

DISEASE MARKERS (2018)

Add to Collection
Article Chemistry, Multidisciplinary

Reprogramming Exosomes as Nanoscale Controllers of Cellular Immunity

Qnqin Cheng et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)

Add to Collection
Review Biotechnology & Applied Microbiology

Exosomes as drug carriers for clinical application

Cuixia Di et al.

ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2018)

Add to Collection
Article Surgery

Outside-in HLA class I signaling regulates ICAM-1 clustering and endothelial cell-monocyte interactions via mTOR in transplant antibody-mediated rejection

Sahar Salehi et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2018)

Add to Collection
Article Chemistry, Multidisciplinary

Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting

Seung Min Kim et al.

JOURNAL OF CONTROLLED RELEASE (2017)

Add to Collection
Review Biochemistry & Molecular Biology

Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development

Hua-fu Zhao et al.

MOLECULAR CANCER (2017)

Add to Collection
Article Oncology

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

Trisha M. Wise-Draper et al.

TARGETED ONCOLOGY (2017)

Add to Collection
Article Multidisciplinary Sciences

The mTORC1-4E-BP-eIF4E axis controls de novo Bcl6 protein synthesis in T cells and systemic autoimmunity

Woelsung Yi et al.

NATURE COMMUNICATIONS (2017)

Add to Collection
Article Multidisciplinary Sciences

Covalent modification of pericardial patches for sustained rapamycin delivery inhibits venous neointimal hyperplasia

Hualong Bai et al.

SCIENTIFIC REPORTS (2017)

Add to Collection
Article Oncology

Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms

Inan Olmez et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection
Article Oncology

A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma

Qiwen Fan et al.

CANCER CELL (2017)

Add to Collection
Article Pharmacology & Pharmacy

Co-delivery of rapamycin- and piperine-loaded polymeric nanoparticles for breast cancer treatment

Sameer S. Katiyar et al.

DRUG DELIVERY (2016)

Add to Collection
Article Biochemistry & Molecular Biology

Hypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells

Shuyang Chen et al.

JOURNAL OF CELLULAR BIOCHEMISTRY (2016)

Add to Collection
Article Oncology

Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models

I. A. Netland et al.

BMC CANCER (2016)

Add to Collection
Review Cell Biology

4E-BP1, a multifactor regulated multifunctional protein

Xiaoyu Qin et al.

CELL CYCLE (2016)

Add to Collection
Review Genetics & Heredity

Role of mTOR in glioblastoma

Zekeriya Duzgun et al.

GENE (2016)

Add to Collection
Article Multidisciplinary Sciences

Cell type-specific control of protein synthesis and proliferation by FGF-dependent signaling to the translation repressor 4E-BP

Rachel Ruoff et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)

Add to Collection
Article Chemistry, Medicinal

Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR

Timothy P. Heffron et al.

ACS MEDICINAL CHEMISTRY LETTERS (2016)

Add to Collection
Article Cell & Tissue Engineering

Intra-articular injection of Torin 1 reduces degeneration of articular cartilage in a rabbit osteoarthritis model

N-T. Cheng et al.

BONE & JOINT RESEARCH (2016)

Add to Collection
Article Oncology

NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells

Zhiyun Yu et al.

CANCER LETTERS (2015)

Add to Collection
Article Oncology

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

Geoffrey I. Shapiro et al.

CLINICAL CANCER RESEARCH (2015)

Add to Collection
Article Pharmacology & Pharmacy

Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of intracranial glioma

Kyle T. Householder et al.

INTERNATIONAL JOURNAL OF PHARMACEUTICS (2015)

Add to Collection
Article Chemistry, Multidisciplinary

Targeted therapy of colorectal neoplasia with rapamycin in peptide-labeled pegylated octadecyl lithocholate micelles

Supang Khondee et al.

JOURNAL OF CONTROLLED RELEASE (2015)

Add to Collection
Article Chemistry, Multidisciplinary

Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells

Heikki Saari et al.

JOURNAL OF CONTROLLED RELEASE (2015)

Add to Collection
Article Oncology

miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients

Johnny C. Akers et al.

JOURNAL OF NEURO-ONCOLOGY (2015)

Add to Collection
Article Oncology

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Sylvie M. Guichard et al.

MOLECULAR CANCER THERAPEUTICS (2015)

Add to Collection
Article Multidisciplinary Sciences

Curcumin Modulates Pancreatic Adenocarcinoma Cell-Derived Exosomal Function

Carlos J. Diaz Osterman et al.

PLOS ONE (2015)

Add to Collection
Article Materials Science, Biomaterials

Self-assembled micelles of amphiphilic PEGylated rapamycin for loading paclitaxel and resisting multidrug resistant cancer cells

Wei Tian et al.

JOURNAL OF MATERIALS CHEMISTRY B (2015)

Add to Collection
Article Biochemistry & Molecular Biology

mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling

Huiyuan Zhang et al.

APOPTOSIS (2015)

Add to Collection
Article Chemistry, Multidisciplinary

Co-delivery of Cisplatin and Rapamycin for Enhanced Anticancer Therapy through Synergistic Effects and Microenvironment Modulation

Shutao Guo et al.

ACS NANO (2014)

Add to Collection
Article Oncology

Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma

Carlos Rodrigo Gil del Alcazar et al.

CLINICAL CANCER RESEARCH (2014)

Add to Collection
Article Ophthalmology

Cholesterol-poly(ethylene) glycol nanocarriers for the transscleral delivery of sirolimus

Naba Elsaid et al.

EXPERIMENTAL EYE RESEARCH (2014)

Add to Collection
Article Oncology

The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells

Jenna Kahn et al.

NEURO-ONCOLOGY (2014)

Add to Collection
Article Oncology

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02

Patrick Y. Wen et al.

NEURO-ONCOLOGY (2014)

Add to Collection
Article Oncology

The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells

Shuyu Li et al.

CANCER CELL INTERNATIONAL (2013)

Add to Collection
Article Oncology

Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth

Mark Katakowski et al.

CANCER LETTERS (2013)

Add to Collection
Article Biotechnology & Applied Microbiology

Genetically Engineered Microvesicles Carrying Suicide mRNA/Protein Inhibit Schwannoma Tumor Growth

Arda Mizrak et al.

MOLECULAR THERAPY (2013)

Add to Collection
Article Multidisciplinary Sciences

Coibamide A Induces mTOR-Independent Autophagy and Cell Death in Human Glioblastoma Cells

Andrew M. Hau et al.

PLOS ONE (2013)

Add to Collection
Article Biotechnology & Applied Microbiology

Enhanced solubility and oral absorption of sirolimus using D-α-tocopheryl polyethylene glycol succinate micelles

Min-Soo Kim et al.

ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2013)

Add to Collection
Article Cell Biology

New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis

Maria Comas et al.

AGING-US (2012)

Add to Collection
Article Oncology

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

A. Naing et al.

BRITISH JOURNAL OF CANCER (2012)

Add to Collection
Review Biochemistry & Molecular Biology

mTOR Signaling in Growth Control and Disease

Mathieu Laplante et al.

CELL (2012)

Add to Collection
Article Oncology

Abstract B146: XL388: A novel, selective, orally bioavailable mTORC1 and mTORC2 inhibitor that demonstrates pharmacodynamic and antitumor activity in multiple human cancer xenograft models

N. Miller

MOLECULAR CANCER THERAPEUTICS (2012)

Add to Collection
Article Oncology

Antitumor Activity of Triolimus: A Novel Multidrug-Loaded Micelle Containing Paclitaxel, Rapamycin, and 17-AAG

Jason R. Hasenstein et al.

MOLECULAR CANCER THERAPEUTICS (2012)

Add to Collection
Article Oncology

Clinicopathological significance of cathepsin D expression in non-small cell lung cancer is conditional on apoptosis-associated protein phenotype: an immunohistochemistry study

Chuifeng Fan et al.

TUMOR BIOLOGY (2012)

Add to Collection
Article Oncology

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage Responses

Bipasha Mukherjee et al.

NEOPLASIA (2012)

Add to Collection
Article Ophthalmology

Positively Charged Amphiphilic Chitosan Derivative for the Transscleral Delivery of Rapamycin

Naba Elsaid et al.

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2012)

Add to Collection
Article Pharmacology & Pharmacy

Inhibition of Autophagy as a Strategy to Augment Radiosensitization by the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235

George J. Cerniglia et al.

MOLECULAR PHARMACOLOGY (2012)

Add to Collection
Article Surgery

Rapamycin-Loaded Nanoparticles for Inhibition of Neointimal Hyperplasia in Experimental Vein Grafts

Junjie Zou et al.

ANNALS OF VASCULAR SURGERY (2011)

Add to Collection
Article Oncology

A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell-Delivered TRAIL in Experimental Glioma Models

Tugba Bagci-Onder et al.

CANCER RESEARCH (2011)

Add to Collection
Article Chemistry, Multidisciplinary

Nano-sized drug-loaded micelles deliver payload to lymph node immune cells and prolong allograft survival

Karen Y. Dane et al.

JOURNAL OF CONTROLLED RELEASE (2011)

Add to Collection
Article Chemistry, Medicinal

Poly(ethylene glycol)-Block-Poly(2-methyl-2-benzoxycarbonyl-propylene Carbonate) Micelles for Rapamycin Delivery: In Vitro Characterization and Biodistribution

Wenli Lu et al.

JOURNAL OF PHARMACEUTICAL SCIENCES (2011)

Add to Collection
Article Oncology

Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide

Gautam Prasad et al.

NEURO-ONCOLOGY (2011)

Add to Collection
Article Oncology

Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells

Jun Sunayama et al.

NEURO-ONCOLOGY (2010)

Add to Collection
Article Oncology

FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma

Virginia E. Kwitkowski et al.

ONCOLOGIST (2010)

Add to Collection
Article Biochemistry & Molecular Biology

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

Juan M. Garcia-Martinez et al.

BIOCHEMICAL JOURNAL (2009)

Add to Collection
Article Oncology

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Ker Yu et al.

CANCER RESEARCH (2009)

Add to Collection
Article Oncology

A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies

Christine M. Hartford et al.

CLINICAL CANCER RESEARCH (2009)

Add to Collection
Article Biochemistry & Molecular Biology

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

Carson C. Thoreen et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2009)

Add to Collection
Article Oncology

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

Ta-Jen Liu et al.

MOLECULAR CANCER THERAPEUTICS (2009)

Add to Collection
Article Biochemistry & Molecular Biology

The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair

M-A Westhoff et al.

ONCOGENE (2009)

Add to Collection
Article Biochemistry & Molecular Biology

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

Morris E. Feldman et al.

PLOS BIOLOGY (2009)

Add to Collection
Article Oncology

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations

Violeta Serra et al.

CANCER RESEARCH (2008)

Add to Collection
Article Biochemistry & Molecular Biology

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

Beth Apsel et al.

NATURE CHEMICAL BIOLOGY (2008)

Add to Collection
Article Oncology

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

E Raymond et al.

JOURNAL OF CLINICAL ONCOLOGY (2004)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.